Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care.

The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.

Nelson Advisors thought leadership has been referenced in the Forbes article '5 High-Growth Business Models Set To Thrive In The Coming Decade' outlining five business models that are primed for success in the coming years.

The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.

The German Digital Health Act (DiGA), a foundational element of Germany's broader digital healthcare transformation, represents a pioneering legislative initiative to integrate digital health applications into mainstream medical care. Initiated by the Digital Healthcare Act (DVG) in 2019 and further bolstered by the Digital Act (DigiG) in 2024, this framework enables "apps on prescription" to be reimbursed by statutory health insurers, covering approximately 90% of the German

Private equity firms have traditionally focused on investing in large, high-growth healthcare technology companies. However, there is a growing opportunity for private equity firms to tap into the midtier of the healthtech landscape. These midtier companies have demonstrated a proof of concept, have won flagship customers, and are consistently profitable. However, they are unlikely to reach billion-dollar valuations. This makes them attractive targets for private equity fi